The Cell and Gene Therapy Catapult’s state-of-the-art Manufacturing Innovation Centre located in Stevenage, is at the centre of the largest cluster of cell and gene therapy companies outside the US.
27% of European advanced therapy medicinal products (ATMPs) companies are operating in the UK, where there are now more than 90 advanced therapy developers, compared to only 22 in 2012. In 2020 there was a 50% increase in the number of ATMPs clinical trials run in the UK, bringing this number to 154, accounting for 12% of all global ATMP clinical trials, and these numbers are predicted to increase further.
Within the growing ATMP industry, there is an increasing academic and commercial demand for new development and manufacturing capabilities for clinical trial supply, including viral vectors supply. In February 2021, Rentschler Biopharma SE, a leading global contract development and manufacturing organisation, and Cell and Gene Therapy Catapult entered into a collaboration to enable Rentschler to set up their new processes and capabilities whilst enabling the establishment of new capacity for the UK to benefit from the national and international ATMP supply chain. Rentschler Biopharma will make a significant investment to set up their ATMP development and manufacturing capabilities at the Stevenage site over five years, and will leverage the Cell and Gene Therapy Catapult’s expertise in ATMP manufacturing, as well as benefit from the clusters and ecosystem that have developed around Stevenage and across the UK.
The investment in the UK cell and gene therapy industry is expected to further accelerate the development of the vital infrastructure and skilled jobs needed to meet the rising demand for manufacturing capacity in the UK and globally, and streamline the supply chain for these advanced therapies.